Life sciences companies are rushing to find ways to diagnose, prevent and treat the COVID-19 virus. They face legal challenges, from regulatory oversight to supply chain disruption and product liability. What are the opportunities in trying to solve the COVID-19 virus puzzle? And how do these global innovators handle the risks? Our latest episode of The Sidley Podcast grapples with those questions and many others. Join host and Sidley partner Sam Gandhi as he speaks with two of Sidley’s thought leaders on the critical issues that life sciences companies face—Becky Wood, who leads Sidley’s FDA regulatory practice, and Doro Schramm, an international arbitration partner in the firm’s Geneva, Switzerland office. Together, they address what businesses can do in anticipation of the challenges ahead.